Report

  1. Home
  2. Discounted reports

Patented Drugs Market By Dosage Form (Solid Drug Product, Liquid Drug Product, Others), By Indication (Cardiovascular Diseases, Cancer, Autoimmune Diseases, Others), By Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

Market Report I 2023-08-01 I 263 Pages I Allied Market Research
Discounted by 10% to 2024-11-15

The patented drugs market was valued at $814.5 billion in 2022 and is estimated to reach $1,456.5billion by 2032, exhibiting a CAGR of 6.0% from 2023 to 2032.Patented drugs are pharmaceutical products that have been granted legal protection through a patent by government authorities, such as U.S. Patent and Trademark Office (USPTO), Intellectual Property Office, Japan Patent Office, and others. A patent is a legal protection that gives the patent holder exclusive rights to manufacture, use, and sell the patented drug for 20 years from the filing date of the patent application. During this period, other companies are prohibited from producing or marketing the same drug without permission from the patent holder. Patented drugs are the result of significant research and development efforts, and patents serve as a mechanism to protect and incentivize innovation in the pharmaceutical industry.
The patented drugs market growth is driven by increase in the number of research activities for development of new drugs, advancement in biotechnology and 3D modeling, and rise in people suffering from chronic diseases. Researchers explore various disease mechanisms, molecular pathways, and drug targets to identify potential areas for therapeutic intervention. This creates opportunities for the development of new drugs which drives the growth of patented drugs market. Furthermore, the prevalence of chronic diseases, such as cardiovascular diseases, cancer, diabetes, respiratory disorders, and neurological conditions, has been steadily rising globally. For instance, in 2021 American Cancer Society (ACS), estimated that about 1.9 million new cancer cases were diagnosed in the U.S. The available patented drugs for cancer include Avastin, KYPROLIS, IBRANCE, and others. This rise in chronic diseases has led to a higher demand for effective treatments and management strategies, which in turn drives the growth of the patented drugs market.
In addition, the availability of robust regulatory authorities such as U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) determines the drug approval process and grant market exclusivity to pharmaceuticals. This exclusivity period provide advantages for pharmaceutical companies, enabling them to recover their investment and generate revenue from patented drugs. Furthermore, increase in number of patent application filing in 2022 further boost the growth of the patented drugs market. For instance, in 2022, European Patent Office (EPO), received a total of 193,460 applications. It was also reported that patent activity in pharmaceuticals increased by 1% as compared to 2021.
However, entry of generic versions of the drug at lower prices after patent expiration limit the growth of the patented drugs market. The availability of cheaper alternatives may impact the demand for patented drugs. Furthermore, high costs associated with new drug development is financially challenging for pharmaceutical companies and limit their ability to invest in innovation and develop new patented drugs thereby impacting the market growth. On the other hand, surge in technological advancements, such as precision medicine, genomics, proteomics, and targeted therapies, are revolutionizing drug discovery and development. These advancements enable the development of more effective and patented drugs during the forecast period.
The patented drugs market is segmented on the basis of dosage form, indication, distribution channel, and region. On the basis of dosage form, the market is classified into solid drug product, liquid drug product, and others. Others segments include semi-solid drug and gaseous drug. As per indication, the market is categorized into cardiovascular diseases, cancer, autoimmune diseases, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global patented drugs market are AbbVie Inc., Amgen Inc., Pfizer Inc., Novartis AG, AstraZeneca plc, Bayer AG, Johnson & Johnson, F. Hoffmann-La Roche AG, Astellas Pharma Inc., and Biogen. Key players operating in the market have adopted patent and patent extension as their key strategies to expand their market share and product portfolio.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the patented drugs market analysis from 2022 to 2032 to identify the prevailing patented drugs market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the patented drugs market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global patented drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Distribution Channel
- Hospital Pharmacies
- Drug Store and Retail Pharmacies
- Online Pharmacies
By Dosage Form
- Solid Drug Product
- Liquid Drug Product
- Others
By Indication
- Cardiovascular Diseases
- Cancer
- Autoimmune Diseases
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Amgen Inc.
- Pfizer Inc.
- AstraZeneca plc
- Bayer AG
- Biogen
- Johnson & Johnson
- Astellas Pharma Inc.
- F. Hoffmann-La Roche AG
- Novartis AG
- AbbVie Inc.

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in investment in research and development activities
3.4.1.2. Surge in disease burden

3.4.2. Restraints
3.4.2.1. High cost of patented drugs

3.4.3. Opportunities
3.4.3.1. Strong intellectual property rights

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: PATENTED DRUGS MARKET, BY DOSAGE FORM
4.1. Overview
4.1.1. Market size and forecast
4.2. Solid Drug Product
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Liquid Drug Product
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: PATENTED DRUGS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cardiovascular Diseases
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Cancer
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Autoimmune Diseases
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug Store and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: PATENTED DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Dosage Form
7.2.3. Market size and forecast, by Indication
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Dosage Form
7.2.5.1.3. Market size and forecast, by Indication
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Dosage Form
7.2.5.2.3. Market size and forecast, by Indication
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Dosage Form
7.2.5.3.3. Market size and forecast, by Indication
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Dosage Form
7.3.3. Market size and forecast, by Indication
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Dosage Form
7.3.5.1.3. Market size and forecast, by Indication
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Dosage Form
7.3.5.2.3. Market size and forecast, by Indication
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Dosage Form
7.3.5.3.3. Market size and forecast, by Indication
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Dosage Form
7.3.5.4.3. Market size and forecast, by Indication
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Dosage Form
7.3.5.5.3. Market size and forecast, by Indication
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Dosage Form
7.3.5.6.3. Market size and forecast, by Indication
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Dosage Form
7.4.3. Market size and forecast, by Indication
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Dosage Form
7.4.5.1.3. Market size and forecast, by Indication
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Dosage Form
7.4.5.2.3. Market size and forecast, by Indication
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Dosage Form
7.4.5.3.3. Market size and forecast, by Indication
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Dosage Form
7.4.5.4.3. Market size and forecast, by Indication
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Dosage Form
7.4.5.5.3. Market size and forecast, by Indication
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Dosage Form
7.4.5.6.3. Market size and forecast, by Indication
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Dosage Form
7.5.3. Market size and forecast, by Indication
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Dosage Form
7.5.5.1.3. Market size and forecast, by Indication
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Dosage Form
7.5.5.2.3. Market size and forecast, by Indication
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Dosage Form
7.5.5.3.3. Market size and forecast, by Indication
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Dosage Form
7.5.5.4.3. Market size and forecast, by Indication
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. AbbVie Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Amgen Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Pfizer Inc.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Novartis AG
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. AstraZeneca plc
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Bayer AG
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Johnson & Johnson
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. F. Hoffmann-La Roche AG
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Biogen
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Astellas Pharma Inc.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 02. PATENTED DRUGS MARKET FOR SOLID DRUG PRODUCT, BY REGION, 2022-2032 ($MILLION)
TABLE 03. PATENTED DRUGS MARKET FOR LIQUID DRUG PRODUCT, BY REGION, 2022-2032 ($MILLION)
TABLE 04. PATENTED DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 06. PATENTED DRUGS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 07. PATENTED DRUGS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 08. PATENTED DRUGS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 09. PATENTED DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 11. PATENTED DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 12. PATENTED DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. PATENTED DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. PATENTED DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA PATENTED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 19. U.S. PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 20. U.S. PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 21. U.S. PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 22. CANADA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 23. CANADA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 24. CANADA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 25. MEXICO PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 26. MEXICO PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 27. MEXICO PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. EUROPE PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 29. EUROPE PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 30. EUROPE PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 31. EUROPE PATENTED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 32. GERMANY PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 33. GERMANY PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 34. GERMANY PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 35. FRANCE PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 36. FRANCE PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 37. FRANCE PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. UK PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 39. UK PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 40. UK PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. ITALY PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 42. ITALY PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 43. ITALY PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 44. SPAIN PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 45. SPAIN PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 46. SPAIN PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC PATENTED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 54. JAPAN PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 55. JAPAN PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 56. JAPAN PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. CHINA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 58. CHINA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 59. CHINA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. INDIA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 61. INDIA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 62. INDIA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 72. LAMEA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 73. LAMEA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 74. LAMEA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 75. LAMEA PATENTED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 76. BRAZIL PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 77. BRAZIL PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 78. BRAZIL PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 88. ABBVIE INC.: KEY EXECUTIVES
TABLE 89. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 90. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 91. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 92. AMGEN INC.: KEY EXECUTIVES
TABLE 93. AMGEN INC.: COMPANY SNAPSHOT
TABLE 94. AMGEN INC.: PRODUCT SEGMENTS
TABLE 95. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 96. PFIZER INC.: KEY EXECUTIVES
TABLE 97. PFIZER INC.: COMPANY SNAPSHOT
TABLE 98. PFIZER INC.: PRODUCT SEGMENTS
TABLE 99. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 100. PFIZER INC.: KEY STRATERGIES
TABLE 101. NOVARTIS AG: KEY EXECUTIVES
TABLE 102. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 103. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 104. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 105. NOVARTIS AG: KEY STRATERGIES
TABLE 106. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 107. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 108. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 109. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 110. BAYER AG: KEY EXECUTIVES
TABLE 111. BAYER AG: COMPANY SNAPSHOT
TABLE 112. BAYER AG: PRODUCT SEGMENTS
TABLE 113. BAYER AG: PRODUCT PORTFOLIO
TABLE 114. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 115. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 116. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 117. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 118. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
TABLE 119. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 120. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
TABLE 121. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 122. BIOGEN: KEY EXECUTIVES
TABLE 123. BIOGEN: COMPANY SNAPSHOT
TABLE 124. BIOGEN: PRODUCT SEGMENTS
TABLE 125. BIOGEN: PRODUCT PORTFOLIO
TABLE 126. BIOGEN: KEY STRATERGIES
TABLE 127. ASTELLAS PHARMA INC.: KEY EXECUTIVES
TABLE 128. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
TABLE 129. ASTELLAS PHARMA INC.: PRODUCT SEGMENTS
TABLE 130. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO

LIST OF FIGURES
FIGURE 01. PATENTED DRUGS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF PATENTED DRUGS MARKET,2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN PATENTED DRUGS MARKET (2023-2032)
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. MODERATE INTENSITY OF RIVALRY
FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
FIGURE 09. GLOBAL PATENTED DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 10. PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR SOLID DRUG PRODUCT, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR LIQUID DRUG PRODUCT, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. PATENTED DRUGS MARKET, BY INDICATION, 2022(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. PATENTED DRUGS MARKET BY REGION, 2022(%)
FIGURE 24. U.S. PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 25. CANADA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 26. MEXICO PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 27. GERMANY PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 28. FRANCE PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 29. UK PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 30. ITALY PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 31. SPAIN PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 32. REST OF EUROPE PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 33. JAPAN PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 34. CHINA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 35. INDIA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 36. AUSTRALIA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 37. SOUTH KOREA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 38. REST OF ASIA-PACIFIC PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 39. BRAZIL PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 40. SAUDI ARABIA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 41. SOUTH AFRICA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 42. REST OF LAMEA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 47. COMPETITIVE DASHBOARD
FIGURE 48. COMPETITIVE HEATMAP: PATENTED DRUGS MARKET
FIGURE 49. TOP PLAYER POSITIONING, 2022
FIGURE 50. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 51. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 54. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 55. AMGEN INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 56. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 57. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 60. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 61. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 62. ASTRAZENECA PLC: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 63. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 64. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 65. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 66. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 67. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 68. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 69. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 70. BIOGEN: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 71. ASTELLAS PHARMA INC.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 72. ASTELLAS PHARMA INC.: REVENUE SHARE BY REGION, 2022 (%)

  • Not Sure / Need Reassuring
    • Confirm Content

      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages

      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives

      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices

      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts

      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies

      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses

      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License

      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats

      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery

      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges

      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card

      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer

      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security

      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security

      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $3456.00 $3110.40
  • $5730.00 $5157.00
  • $9600.00 $8640.00
  • ADD TO BASKET
  • BUY NOW